Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Humoral Immune Response
100%
Investigational Drugs
100%
Investigational Agents
100%
Patients with COVID-19
100%
SARS-CoV-2 Infection
100%
Hospitalized Patients
100%
Discharged Patients
50%
Between-person
50%
Respiratory Disease
50%
Sustained Recovery
50%
Phase II Trial
50%
Multicenter Trial
50%
COVID-19
50%
Novel Coronavirus SARS-CoV-2
50%
Passive Immunity
50%
Anticipated Benefits
50%
Disease Progression
50%
Host Immune Response
50%
Disease Course
50%
Natural History
50%
Nasal Swab
50%
Repurposing
50%
Tissue Damage
50%
Therapeutic Agents
50%
Neutralizing Antibodies
50%
Damage Response
50%
Safety Self-efficacy
50%
Severe COVID-19
50%
Clinical Trials
50%
Viral Control
50%
Safety Assessment
50%
Lung
50%
Hospitalization
50%
Inflammatory Response
50%
COVID-19 Outbreak
50%
Laboratory Assessment
50%
Efficacy Assessment
50%
Consecutive Days
50%
Blood Samples
50%
Recovery Time
50%
Viral Replication
50%
Patient's Will
50%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
100%
Infection
66%
Respiratory Tract Disease
33%
Repurposing
33%
Disease Course
33%
Diseases
33%
Clinical Trial
33%
Tissue Injury
33%
Coronavirinae
33%
Disease Exacerbation
33%
Immunotherapy
33%
Neutralizing Antibody
33%
Inflammation
33%
Immunology and Microbiology
COVID-19
100%
Severe Acute Respiratory Syndrome Coronavirus 2
75%
Humoral Immunity
50%
Host Immune Response
25%
Viral Replication
25%
Neutralizing Antibody
25%
Immunotherapy
25%
Coronavirinae
25%
Inflammation Response
25%